{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:14:40Z","timestamp":1779894880313,"version":"3.53.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00228-019-02798-8","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T23:03:34Z","timestamp":1576019014000},"page":"547-555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Consumption of medicines used for gastric acid-related disorders in Australia and South Korea: a cross-country comparison"],"prefix":"10.1007","volume":"76","author":[{"given":"Su-Yeon","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5117-1377","authenticated-orcid":false,"given":"Boram","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Treasure M.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha A.","family":"Hollingworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"issue":"5","key":"2798_CR1","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/gut.2004.051821","volume":"54","author":"J Dent","year":"2005","unstructured":"Dent J, El-Serag H, Wallander MA, Johansson S (2005) Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 54(5):710\u2013717","journal-title":"Gut"},{"issue":"1","key":"2798_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5056\/jnm.2011.17.1.14","volume":"17","author":"HK Jung","year":"2011","unstructured":"Jung HK (2011) Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil 17(1):14\u201327","journal-title":"J Neurogastroenterol Motil"},{"issue":"6","key":"2798_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","volume":"63","author":"HB El-Serag","year":"2014","unstructured":"El-Serag HB, Sweet S, Winchester CC, Dent J (2014) Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 63(6):871\u2013880","journal-title":"Gut"},{"issue":"7","key":"2798_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067494","volume":"8","author":"C Harrison","year":"2013","unstructured":"Harrison C, Britt H, Miller G, Henderson J (2013) Prevalence of chronic conditions in Australia. PLoS One 8(7):e67494","journal-title":"PLoS One"},{"issue":"5","key":"2798_CR5","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1053\/j.gastro.2012.08.002","volume":"143","author":"AF Peery","year":"2012","unstructured":"Peery AF, Dellon ES, Lund J et al (2012) Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 143(5):1179\u20131187","journal-title":"Gastroenterology"},{"issue":"3","key":"2798_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/11531670-000000000-00000","volume":"30","author":"S Toghanian","year":"2010","unstructured":"Toghanian S, Wahlqvist P, Johnson DA, Bolge SC, Liljas B (2010) The burden of disrupting gastro-oesophageal reflux disease. Clin Drug Investig 30(3):167\u2013178","journal-title":"Clin Drug Investig"},{"key":"2798_CR7","unstructured":"Organization for Economic Cooperation and Development (2016) Focus on Health Spending April 2016. https:\/\/www.oecd.org\/health\/Expenditure-by-disease-age-and-gender-FOCUS-April2016.pdf. Accessed 3 June 2019"},{"issue":"8","key":"2798_CR8","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00535-016-1227-8","volume":"51","author":"K Iwakiri","year":"2016","unstructured":"Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe N, Fujiwara Y, Nagahara A, Kawamura O, Iwakiri R, Ozawa S, Ashida K, Ohara S, Kashiwagi H, Adachi K, Higuchi K, Miwa H, Fujimoto K, Kusano M, Hoshihara Y, Kawano T, Haruma K, Hongo M, Sugano K, Watanabe M, Shimosegawa T (2016) Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol 51(8):751\u2013767","journal-title":"J Gastroenterol"},{"key":"2798_CR9","unstructured":"The National Institute for Health and Care Excellence (NICE). Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management NICE Clinical guideline (CG184). https:\/\/www.nice.org.uk\/guidance\/cg184. Accessed 3 June 2019"},{"issue":"1","key":"2798_CR10","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1007\/s10620-005-2800-9","volume":"50","author":"T Arakawa","year":"2005","unstructured":"Arakawa T, Higuchi K, Fujiwara Y et al (2005) 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci 50(1):S3\u2013S11","journal-title":"Dig Dis Sci"},{"issue":"3","key":"2798_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000211713","volume":"79","author":"T Arakawa","year":"2009","unstructured":"Arakawa T, Fujiwara Y, Sollano JD, Zhu Q, Kachintorn U, Rani AA, Hahm KB, Takahashi S, Joh T, Kinoshita Y, Matsumoto T, Naito Y, Takeuchi K, Yamagami H, Agustanti N, Xiong H, Chen X, Jang EJ, Furuta K, Terano A, IGICS study group (2009) A questionnaire-based survey on the prescription of non-steroidal anti-inflammatory drugs by physicians in East Asian countries in 2007. Digestion 79(3):177\u2013185","journal-title":"Digestion"},{"key":"2798_CR12","volume-title":"The study on drugs used in acid-related disorders","author":"SL Yu","year":"2013","unstructured":"Yu SL, Lee BR, Lee SO et al (2013) The study on drugs used in acid-related disorders. Health Insurance Review and Assessment Service, Seoul"},{"issue":"1","key":"2798_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5009\/gnl16615","volume":"12","author":"DS Sandhu","year":"2018","unstructured":"Sandhu DS, Fass R (2018) Current trends in the management of gastroesophageal reflux disease. Gut Liver 12(1):7","journal-title":"Gut Liver"},{"issue":"6","key":"2798_CR14","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ajem.2014.03.019","volume":"32","author":"M Mazer-Amirshahi","year":"2014","unstructured":"Mazer-Amirshahi M, Mullins PM, van den Anker J, Meltzer A, Pines JM (2014) Rising rates of proton pump inhibitor prescribing in US emergency departments. Am J Emerg Med 32(6):618\u2013622. https:\/\/doi.org\/10.1016\/j.ajem.2014.03.019","journal-title":"Am J Emerg Med"},{"issue":"10","key":"2798_CR15","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/pds.1969","volume":"19","author":"S Hollingworth","year":"2010","unstructured":"Hollingworth S, Duncan EL, Martin JH (2010) Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf 19(10):1019\u20131024. https:\/\/doi.org\/10.1002\/pds.1969","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"975","key":"2798_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/pgmj.2006.051151","volume":"83","author":"BT Batuwitage","year":"2007","unstructured":"Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL (2007) Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 83(975):66\u201368","journal-title":"Postgrad Med J"},{"key":"2798_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/bmj.39406.449456.BE","volume":"336","author":"I Forgacs","year":"2008","unstructured":"Forgacs I, Loganayagam A (2008) Overprescribing proton pump inhibitors. BMJ 336:2\u20133","journal-title":"BMJ"},{"issue":"11","key":"2798_CR18","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1038\/ajg.2011.220","volume":"106","author":"DC Metz","year":"2011","unstructured":"Metz DC, Pilmer BL, Han C, Perez MC (2011) Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data. Am J Gastroenterol 106(11):1953\u20131960","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"2798_CR19","first-page":"3118","volume":"95","author":"RJ Nardino","year":"2000","unstructured":"Nardino RJ, Vender RJ, Herbert PN (2000) Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 95(11):3118\u20133122","journal-title":"Am J Gastroenterol"},{"issue":"6932","key":"2798_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1136\/bmj.308.6932.827","volume":"308","author":"SD Ryder","year":"1994","unstructured":"Ryder SD, O'Reilly S, Miller RJ, Ross J, Jacyna MR, Levi AJ (1994) Long term acid suppressing treatment in general practice. BMJ 308(6932):827\u2013830","journal-title":"BMJ"},{"issue":"2","key":"2798_CR21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamainternmed.2015.7927","volume":"176","author":"AJ Schoenfeld","year":"2016","unstructured":"Schoenfeld AJ, Grady D (2016) Adverse effects associated with proton pump inhibitors. JAMA Intern Med 176(2):172\u2013174","journal-title":"JAMA Intern Med"},{"issue":"2","key":"2798_CR22","first-page":"91","volume":"1","author":"I Truter","year":"2008","unstructured":"Truter I (2008) A review of drug utilization studies and methodologies. Jordan J Pharm Sci 1(2):91\u2013103","journal-title":"Jordan J Pharm Sci"},{"issue":"5","key":"2798_CR23","first-page":"354","volume":"63","author":"B Farrell","year":"2017","unstructured":"Farrell B, Pottie K, Thompson W et al (2017) Deprescribing proton pump inhibitors: evidence-based clinical practice guideline. Can Fam Physician 63(5):354\u2013364","journal-title":"Can Fam Physician"},{"issue":"7","key":"2798_CR24","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/ajg.2017.154","volume":"112","author":"P Moayyedi","year":"2017","unstructured":"Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N (2017) ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol 112(7):988\u20131013. https:\/\/doi.org\/10.1038\/ajg.2017.154","journal-title":"Am J Gastroenterol"},{"key":"2798_CR25","volume-title":"Gastro-oesophageal reflux disease in adults","author":"G Hebbard","year":"2011","unstructured":"Hebbard G (2011) Gastro-oesophageal reflux disease in adults, 5th edn. Digestive Health Foundation, Victoria","edition":"5"},{"issue":"4","key":"2798_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4166\/kjg.2012.60.4.195","volume":"60","author":"HK Jung","year":"2012","unstructured":"Jung HK, Hong SJ, Jo Y, Jeon SW, Cho YK, Lee KJ, Lee JS, Park HJ, Shin ES, Lee SH, Han SU, Korean Society of Neurogastroenterology and Motility (2012) Updated guidelines 2012 for gastroesophageal reflux disease. Korean J Gastroenterol 60(4):195\u2013218","journal-title":"Korean J Gastroenterol"},{"issue":"7","key":"2798_CR27","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/pds.3442","volume":"22","author":"SE Tett","year":"2013","unstructured":"Tett SE, Sketris I, Cooke C, van Zanten SV, Barozzi N (2013) Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada. Pharmacoepidemiol Drug Saf 22(7):735\u2013743. https:\/\/doi.org\/10.1002\/pds.3442","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2798_CR28","unstructured":"World Health Organization (2003) Introduction to drug utilization research. http:\/\/apps.who.int\/medicinedocs\/pdf\/s4876e\/s4876e.pdf. Accessed 3 June 2019"},{"issue":"1","key":"2798_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1365-2125.2009.03410.x","volume":"68","author":"N Barozzi","year":"2009","unstructured":"Barozzi N, Sketris I, Cooke C, Tett S (2009) Comparison of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors use in Australia and Nova Scotia (Canada). Br J Clin Pharmacol 68(1):106\u2013115. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03410.x","journal-title":"Br J Clin Pharmacol"},{"key":"2798_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3389\/fphar.2010.00141","volume":"1","author":"B Godman","year":"2011","unstructured":"Godman B, Shrank W, Andersen M et al (2011) Policies to enhance prescribing efficiency in Europe: findings and future implications. Front Pharmacol 1:141","journal-title":"Front Pharmacol"},{"issue":"6","key":"2798_CR31","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1586\/erp.10.72","volume":"10","author":"B Godman","year":"2010","unstructured":"Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi R, Kalaba M, Laius O, McGinn D, Samaluk V, Sermet C, Schwabe U, Teixeira I, Tilson L, Tulunay FC, Vlahovi\u0107-Pal\u010devski V, Wendykowska K, Wettermark B, Zara C, Gustafsson LL (2010) Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res 10(6):707\u2013722","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"2798_CR32","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1177\/1756283X16650156","volume":"9","author":"A Potteg\u00e5rd","year":"2016","unstructured":"Potteg\u00e5rd A, Broe A, Hallas J, de Muckadell OBS, Lassen AT, L\u00f8drup AB (2016) Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Ther Adv Gastroenterol 9(5):671\u2013678","journal-title":"Ther Adv Gastroenterol"},{"issue":"9","key":"2798_CR33","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3109\/00365521.2013.812140","volume":"48","author":"C Jonasson","year":"2013","unstructured":"Jonasson C, Tvete IF, Hatlebakk JG (2013) Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study. Scand J Gastroenterol 48(9):1010\u20131017. https:\/\/doi.org\/10.3109\/00365521.2013.812140","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"2798_CR34","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4292\/wjgpt.v8.i3.180","volume":"8","author":"C Tosetti","year":"2017","unstructured":"Tosetti C, Nanni I (2017) Use of proton pump inhibitors in general practice. World J Gastrointest Pharmacol Ther 8(3):180\u2013185. https:\/\/doi.org\/10.4292\/wjgpt.v8.i3.180","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"2798_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12913-014-0638-6","volume":"15","author":"W Zeng","year":"2015","unstructured":"Zeng W, Finlayson AE, Shankar S, de Bruyn W, Godman B (2015) Prescribing efficiency of proton pump inhibitors in China: influence and future directions. BMC Health Serv Res 15:11. https:\/\/doi.org\/10.1186\/s12913-014-0638-6","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"2798_CR36","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/imj.12757","volume":"45","author":"PS Nishtala","year":"2015","unstructured":"Nishtala PS, Soo L (2015) Proton pump inhibitors utilisation in older people in New Zealand from 2005 to 2013. Intern Med J 45(6):624\u2013629. https:\/\/doi.org\/10.1111\/imj.12757","journal-title":"Intern Med J"},{"issue":"2","key":"2798_CR37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejim.2007.10.020","volume":"20","author":"G Ntaios","year":"2009","unstructured":"Ntaios G, Chatzinikolaou A, Kaiafa G, Savopoulos C, Hatzitolios A, Karamitsos D (2009) Evaluation of use of proton pump inhibitors in Greece. Eur J Intern Med 20(2):171\u2013173. https:\/\/doi.org\/10.1016\/j.ejim.2007.10.020","journal-title":"Eur J Intern Med"},{"issue":"2","key":"2798_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3164\/jcbn.11-94","volume":"51","author":"JS Lee","year":"2012","unstructured":"Lee JS, Cho JY, Song H, Kim EH, Hahm KB (2012) Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against helicobacter pylori-induced COX-2 expression by inactivating Akt signaling. J Clin Biochem Nutr 51(2):77\u201383","journal-title":"J Clin Biochem Nutr"},{"issue":"6","key":"2798_CR39","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.coph.2008.09.004","volume":"8","author":"C Scarpignato","year":"2008","unstructured":"Scarpignato C, Hunt RH (2008) Proton pump inhibitors: the beginning of the end or the end of the beginning? Curr Opin Pharmacol 8(6):677\u2013684","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"2798_CR40","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3892\/etm.2016.3384","volume":"12","author":"JM Lee","year":"2016","unstructured":"Lee JM, Lim JY, Kim Y, Kim YJ, Choi HS, Kim ES, Keum B, Seo YS, Jeen YT, Lee HS, Um SH, Kim CD, Ryu HS, Sul D, Hong J, Chun HJ (2016) Benexate hydrochloride betadex modulates nitric oxide synthesis and cytokine expression in gastric ulcers. Exp Ther Med 12(2):573\u2013580","journal-title":"Exp Ther Med"},{"issue":"1","key":"2798_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4291\/wjgp.v5.i1.40","volume":"5","author":"N Kangwan","year":"2014","unstructured":"Kangwan N, Park JM, Kim EH, Hahm KB (2014) Quality of healing of gastric ulcers: natural products beyond acid suppression. World J Gastrointest Pathophysiol 5(1):40","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"1","key":"2798_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3164\/jcbn.38.1","volume":"38","author":"M Yeo","year":"2006","unstructured":"Yeo M, Kwak MS, Kim DK et al (2006) The novel acid pump antagonists for anti-secretory actions with their peculiar applications beyond acid suppression. J Clin Biochem Nutr 38(1):1\u20138","journal-title":"J Clin Biochem Nutr"},{"key":"2798_CR43","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology ATC\/DDD Index. World Health Organization. https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed 10 Nov 2018"},{"key":"2798_CR44","doi-asserted-by":"publisher","unstructured":"Organization for Economic Cooperation and Development (2019) Exchange rates (indicator). https:\/\/doi.org\/10.1787\/037ed317-en. Accessed 31 Oct 2019","DOI":"10.1787\/037ed317-en"},{"issue":"2","key":"2798_CR45","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s002280050431","volume":"54","author":"U Bergman","year":"1998","unstructured":"Bergman U, Popa C, Tomson Y, Wettermark B, Einarson TR, Aberg H, Sj\u00f6qvist F (1998) Drug utilization 90% - a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol 54(2):113\u2013118","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"2798_CR46","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.pop.2017.07.001","volume":"44","author":"R Kellerman","year":"2017","unstructured":"Kellerman R, Kintanar T (2017) Gastroesophageal reflux disease. Prim Care 44(4):561\u2013573","journal-title":"Prim Care"},{"issue":"9","key":"2798_CR47","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1056\/NEJM200408263510924","volume":"351","author":"RJ Noel","year":"2004","unstructured":"Noel RJ, Putnam PE, Rothenberg ME (2004) Eosinophilic esophagitis. N Engl J Med 351(9):940\u2013941","journal-title":"N Engl J Med"},{"issue":"12","key":"2798_CR48","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/S1542-3565(05)00885-2","volume":"3","author":"CA Liacouras","year":"2005","unstructured":"Liacouras CA, Spergel JM, Ruchelli E, Verma R, Mascarenhas M, Semeao E, Flick J, Kelly J, Brown-Whitehorn T, Mamula P, Markowitz JE (2005) Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol 3(12):1198\u20131206","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2798_CR49","unstructured":"Statistics Korea Population Projections. http:\/\/kosis.kr\/statHtml\/statHtml.do?orgId=101&tblId=DT_1BPA401&conn_path=I2&language=en. Accessed 10 Jan 2019"},{"key":"2798_CR50","unstructured":"Australian Bureau of Statistics Estimated Resident Population. http:\/\/stat.data.abs.gov.au\/. Accessed 10 Jan 2019"},{"issue":"6","key":"2798_CR51","doi-asserted-by":"publisher","first-page":"e98043","DOI":"10.1371\/journal.pone.0098043","volume":"9","author":"HA Kim","year":"2014","unstructured":"Kim HA, Shin JY, Kim MH, Park BJ (2014) Prevalence and predictors of polypharmacy among Korean elderly. PLoS One 9(6):e98043","journal-title":"PLoS One"},{"issue":"2","key":"2798_CR52","doi-asserted-by":"publisher","first-page":"71","DOI":"10.5694\/mja2.50244","volume":"211","author":"AT Page","year":"2019","unstructured":"Page AT, Falster MO, Litchfield M, Pearson SA, Etherton-Beer C (2019) Polypharmacy among older Australians, 2006\u20132017: a population-based study. Med J Aust 211(2):71\u201375","journal-title":"Med J Aust"},{"key":"2798_CR53","doi-asserted-by":"publisher","unstructured":"Park HL, Lee HS, Shin BC et al (2012) Traditional medicine in China, Korea, and Japan: a brief introduction and comparison. Evidence-based complementary and alternative medicine 429103 https:\/\/doi.org\/10.1155\/2012\/429103","DOI":"10.1155\/2012\/429103"},{"key":"2798_CR54","unstructured":"Chaudhury RR, Rafei UM (eds) (2001) Traditional medicine in Asia. World Health Organization Regional Office for South-East Asiaanization. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/206025\/B0104.pdf?sequence=1&isAllowed=y. Accessed 15 Nov 2018"},{"issue":"11","key":"2798_CR55","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/17512433.2018.1531703","volume":"11","author":"V Savarino","year":"2018","unstructured":"Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, de Maria C, Pellegatta G, Coppo C, Savarino E (2018) Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol 11(11):1123\u20131134","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"2798_CR56","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/bcp.12619","volume":"80","author":"S Cohen","year":"2015","unstructured":"Cohen S, Bueno de Mesquita M, Mimouni FB (2015) Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review. Br J Clin Pharmacol 80(2):200\u2013208","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2798_CR57","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4292\/wjgpt.v5.i3.105","volume":"5","author":"R Badillo","year":"2014","unstructured":"Badillo R, Francis D (2014) Diagnosis and treatment of gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther 5(3):105\u2013112","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"9","key":"2798_CR58","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/pds.4043","volume":"25","author":"F Othman","year":"2016","unstructured":"Othman F, Card TR, Crooks CJ (2016) Proton pump inhibitor prescribing patterns in the UK: a primary care database study. Pharmacoepidemiol Drug Saf 25(9):1079\u20131087. https:\/\/doi.org\/10.1002\/pds.4043","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"2798_CR59","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/pds.1664","volume":"17","author":"ML Van Driel","year":"2008","unstructured":"Van Driel ML, Vander Stichele R, Elseviers M, De Sutter A, De Maeseneer J, Christiaens T (2008) Effects of an evidence report and policies lifting reimbursement restrictions for acid suppressants: analysis of the Belgian national database. Pharmacoepidemiol Drug Saf 17(11):1113\u20131122","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2798_CR60","unstructured":"News Medical Life Sciences (2015) NPS MedicineWise program focuses on optimal use of PPI therapy in GORD patients. https:\/\/www.news-medical.net\/news\/20150401\/NPS-MedicineWise-program-focuses-on-optimal-use-of-PPI-therapy-in-GORD-patients.aspx. Accessed 1 Nov 2019"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02798-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T02:02:38Z","timestamp":1607479358000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02798-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["2798"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02798-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,10]]},"assertion":[{"value":"4 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets during and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}